Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab IV vs SC in Psoriatic Arthritis and Axial Spondyloarthritis
NCT07290036Phase 1Recruiting
- Sponsor
- UCB
- Start
- Dec 2025
- Primary completion
- May 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, open-label trial of bimekizumab in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) (2 arms), sponsored by UCB. Primary endpoint: Steady-state Trough Concentration at 16 weeks. Started Dec 2025; status: recruiting.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT07290036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290036.